跳轉至內容
Merck
全部照片(2)

Key Documents

A79809

Sigma-Aldrich

5-氨基水杨酸

95%

同義詞:

5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸

登入查看組織和合約定價


About This Item

線性公式:
H2NC6H3-2-(OH)CO2H
CAS號碼:
分子量::
153.14
Beilstein:
2090421
EC號碼:
MDL號碼:
分類程式碼代碼:
12352106
PubChem物質ID:
NACRES:
NA.22

品質等級

化驗

95%

形狀

powder with small lumps

反應適用性

reaction type: solution phase peptide synthesis

mp

275-280 °C (dec.) (lit.)

應用

detection
peptide synthesis

SMILES 字串

Nc1ccc(O)c(c1)C(O)=O

InChI

1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)

InChI 密鑰

KBOPZPXVLCULAV-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

應用

5-氨基水杨酸是适用于ELISA分析的过氧化物酶底物。这一底物产生可溶性的棕色终产物,可在450nm处通过分光光度法读取。使用3 N NaOH可终止反应并在550 nm处读取结果。

象形圖

Exclamation mark

訊號詞

Warning

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

13 - Non Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

No data available

閃點(°C)

No data available

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

W Kruis et al.
Alimentary pharmacology & therapeutics, 37(7), 680-690 (2013-02-19)
Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse. To investigate mesalazine (Salofalk granules) in this setting. In a double-blind, placebo-controlled, multicentre, 6-week trial, patients were randomised to mesalazine 1000 mg three times daily or placebo.
Urpo Nieminen et al.
International journal of cancer, 134(1), 189-196 (2013-06-26)
Patients with long-standing inflammatory bowel disease (IBD) have an increased risk for colorectal carcinoma (CRC). Earlier studies suggest that the severity of inflammation is an independent risk factor for CRC in ulcerative colitis (UC). We investigated the role of histological
Mirjana Rajilić-Stojanović et al.
Inflammatory bowel diseases, 19(3), 481-488 (2013-02-07)
Presence of intestinal microbes is a prerequisite for the development of ulcerative colitis (UC), although deviation of the normal intestinal microbiota composition, dysbiosis, is presumably implicated in the etiology of UC. The fecal microbiota of 30 UC samples obtained from
Christian P Selinger et al.
Inflammatory bowel diseases, 19(10), 2199-2206 (2013-08-01)
Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets
B Flourié et al.
Alimentary pharmacology & therapeutics, 37(8), 767-775 (2013-03-05)
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. To compare the efficacy and safety of once- (OD) vs. twice- (BD) daily prolonged-release mesalazine (Pentasa, Ferring, Saint-Prex, Switzerland) for active mild-to-moderate UC in a

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務